Discounting hit J&J's Xarelto hard. Can a new launch turn things around?

Competition and discounting are understandably plaguing Johnson & Johnson's older drugs. But its cardiovascular blockbuster Xarelto is also on that list.

The New Jersey drugmaker reported a 14.4% dip in fourth-quarter sales for the anticoagulant, which competes against Pfizer and Bristol-Myers Squibb's hotshot Eliquis and Boehringer Ingelheim's Pradaxa.